GDE1: A Negative Regulator of RhoA GTPase and Potential Drug Target

Target Name: GDE1

NCBI ID: G51573

GDE1

GDE1: A Negative Regulator of RhoA GTPase and Potential Drug Target

GDE1 (Membrane-interacting protein of RGS16) is a protein that is expressed in various tissues and cell types, including the brain, heart, and kidneys. It is a member of the Rho family of G proteins, which are involved in cell signaling and cytoskeletal organization. GDE1 is characterized by its ability to interact with various membrane-bound proteins, including its own associated protein, RGS16.

GDE1 functions as a negative regulator of the RhoA GTPase, which is involved in the regulation of cell signaling pathways. It does this by interacting with RGS16, which is a GTPase that is itself regulated by the RhoA GTPase. This interaction between GDE1 and RGS16 allows for the regulation of RGS16 activity, which in turn affects the levels of various cellular signaling pathways.

GDE1 has been shown to play a role in a number of cellular processes, including cell division, migration, and the regulation of ion and water transport. It has also been shown to be involved in the development and maintenance of various diseases, including cancer and neurodegenerative diseases.

One potential drug target for GDE1 is the inhibition of its activity, which could lead to the regulation of RGS16 activity and the inhibition of cellular signaling pathways. This could have potential therapeutic applications in a variety of diseases, including cancer, neurodegenerative diseases, and systemic inflammation.

Another potential biomarker for GDE1 is its ability to interact with certain proteins that are known to be involved in the development and progression of various diseases. For example, GDE1 has been shown to interact with the protein PDGF-尾, which is involved in the development and maintenance of cancer. This interaction suggests that GDE1 may be a potential drug target for cancer treatment.

In addition to its potential therapeutic and biomarker applications, GDE1 is also of interest to researchers because of its unique structure and mechanism of interaction. GDE1 is a 21-kDa protein that contains a N-terminal domain of 14 amino acids, a catalytic domain of 12 amino acids, and a C-terminal domain of 9 amino acids. It has a unique arrangement of its amino acid residues, with the N-terminal and C-terminal domains arranged in a alternating pattern.

The structure of GDE1 also allows for the regulation of its activity by various chemical modifications, such as phosphorylation and ubiquitination. These modifications can alter the stability and localization of GDE1, which can in turn affect its interaction with RGS16 and other membrane-bound proteins.

In conclusion, GDE1 is a protein that is of interest to researchers due to its unique structure and mechanism of interaction. Its regulation by the RhoA GTPase and its ability to interact with various membrane-bound proteins make it a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of GDE1 in cellular signaling pathways and its potential therapeutic and biomarker applications.

Protein Name: Glycerophosphodiester Phosphodiesterase 1

Functions: Hydrolyzes the phosphodiester bond of glycerophosphodiesters such as glycerophosphoinositol (GroPIns) and glycerophosphoethanolamine (GroPEth), to yield a glycerol phosphate and an alcohol (By similarity). Hydrolyzes glycerophospho-N-acylethanolamines to N-acylethanolamines in the brain and participates in bioactive N-acylethanolamine biosynthesis such as anandamide (an endocannabinoid), N-palmitoylethanolamine (an anti-inflammatory), and N-oleoylethanolamine (an anorexic). In addition, has a lysophospholipase D activity by hydrolyzing N-acyl-lysoplasmenylethanolamine (N-acyl-lysoPlsEt) to N-acylethanolamine. However lysophospholipase D activity is lower than glycerophosphodiester phosphodiesterase activity (By similarity). Has little or no activity towards glycerophosphocholine (By similarity)

The "GDE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GDE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets